Cytoplasts from two-cell embryos for nuclear transplantation in the mouse.

Folia Biol (Praha)

Institute of Molecular Genetics, Czechoslovak Academy of Sciences, Praha.

Published: May 1990

Cytoplasts for nuclear transplantation were prepared by microsurgical enucleation of one or both blastomeres of C57BL/6J and 129/Sv-ter 2-cell embryos. The survival of cytoplasts was high (85 to 97%) in both inbred strains. When cytoplasts with a "doubled" amount of cytoplasm were prepared by electrofusion of enucleated blastomeres in individual embryos, the fusion rate in C57BL/6J embryos was 93% while in 129/Sv-ter only 2%. Similar fusion rates were obtained for C57BL/6J (100%) and 129/Sv-ter (7%) embryos when enucleated and intact blastomeres were fused. The live foetuses and young born after transfer of manipulated embryos into day-1 recipients showed that enucleation and electrofusion were compatible with normal pre- and post-natal development.

Download full-text PDF

Source

Publication Analysis

Top Keywords

nuclear transplantation
8
embryos
6
cytoplasts
4
cytoplasts two-cell
4
two-cell embryos
4
embryos nuclear
4
transplantation mouse
4
mouse cytoplasts
4
cytoplasts nuclear
4
transplantation prepared
4

Similar Publications

Ischemia-reperfusion injury (IRI) is a major obstacle in liver transplantation, especially with steatotic donor livers. Dysbiosis of the gut microbiota has been implicated in modulating IRI, and plays a pivotal role in regulating host inflammatory and immune responses, but its specific role in liver transplantation IRI remains unclear. This study explores whether can mitigate IRI and its underlying mechanisms.

View Article and Find Full Text PDF

CD7-targeted chimeric antigen receptor-T (CAR-T) cell therapy has shown great promise in the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL). In this study, we reported a case of a 34-year-old male patient with T-ALL who finally developed multi-line drug resistance and refractoriness after multiple lines of high-intensity chemotherapy. After physician evaluation, this patient received allogeneic hematopoietic stem cell transplantation (allo-HSCT).

View Article and Find Full Text PDF

Highly efficient construction of monkey blastoid capsules from aged somatic cells.

Nat Commun

January 2025

State Key Laboratory of Primate Biomedical Research; Institute of Primate Translational Medicine, Kunming University of Science and Technology, Kunming, Yunnan, China.

Blastoids-blastocyst-like structures created in vitro-emerge as a valuable model for early embryonic development research. Non-human primates stem cell-derived blastoids are an ethically viable alternative to human counterparts, yet the low formation efficiency of monkey blastoid cavities, typically below 30%, has limited their utility. Prior research has predominantly utilized embryonic stem cells.

View Article and Find Full Text PDF

Hepatosplenic T-cell lymphoma in children and adolescents.

Blood Adv

January 2025

Univeristy of Alabama at Birmingham, Birmingham, Alabama, United States.

Hepatosplenic T-cell lymphoma (HSTCL) is an aggressive mature T-cell lymphoma characterized by significant hepatosplenomegaly, bone marrow involvement, and minimal or no lymphadenopathy. Primarily affecting young adults, it is exceptionally rare in children and adolescents. This makes diagnosis and treatment particularly challenging for pathologists and pediatric oncologists.

View Article and Find Full Text PDF

ConspectusThe discovery of reversible hydrogenation using metal-free phosphoborate species in 2006 marked the official advent of frustrated Lewis pair (FLP) chemistry. This breakthrough revolutionized homogeneous catalysis approaches and paved the way for innovative catalytic strategies. The unique reactivity of FLPs is attributed to the Lewis base (LB) and Lewis acid (LA) sites either in spatial separation or in equilibrium, which actively react with molecules.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!